MICHELLE KABAKIBI: Open Payments
NPI 1154849909 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$459 in 19 payments from 11 companies in 2025. Trend: 2023 $311 · 2024 $432 · 2025 $459
Food & beverage: $459
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 4 | $119 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $49 |
| ABBVIE INC. | 2 | $46 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $42 |
| ABIOMED | 2 | $41 |
| Soleno Therapeutics, Inc. | 2 | $36 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| GENZYME CORPORATION | 1 | $30 |
| Neurocrine BioSciences, Inc. | 1 | $22 |
| Novo Nordisk Inc | 1 | $22 |
Products named: Briviact, CAPLYTA, XIFAXAN, Nayzilam, VYKAT XR, Auvelity, CERDELGA, VRAYLAR.
Industry payments across CA — which companies pay providers there.
